Incretin Atlas › Trials › LEADER
LEADER
Liraglutide · T2D at high CV risk
Design
- Molecule(s)
- Liraglutide
- Population
- T2D at high CV risk
- Official title
- Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
- Sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Registry status
- completed · 2010-08 → 2015-12
- Participants
- 9341
- Registry
- NCT01179048
Cardiovascular and kidney outcomes
LEADER liraglutide 1.8 mg vs placebo · T2D at high CV risk · n = 9340 · 2016 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| 3-point MACE primary First occurrence of CV death, nonfatal (including silent) MI, or nonfatal stroke | 0.87 | 0.78–0.97 | 608 vs 694 | verified |
| Cardiovascular death Death from cardiovascular causes | 0.78 | 0.66–0.93 | 219 vs 278 | verified |
| All-cause death Death from any cause | 0.85 | 0.74–0.97 | 381 vs 447 | verified |
| Myocardial infarction Myocardial infarction (fatal or nonfatal); not prespecified analysis | 0.86 | 0.73–1.00 | 292 vs 339 | verified |
| Stroke Stroke (fatal or nonfatal); not prespecified analysis | 0.86 | 0.71–1.06 | 173 vs 199 | verified |
| Hospitalisation for heart failure Hospitalization for heart failure | 0.87 | 0.73–1.05 | 218 vs 248 | verified |
| Kidney composite Nephropathy: new-onset persistent macroalbuminuria, doubling of serum creatinine with eGFR <=45, continuous renal-replacement therapy, or death from renal disea | 0.78 | 0.67–0.92 | 268 vs 337 | verified |
| Expanded MACE (MACE + HF hosp. + revasc. + UA) Expanded composite: death from CV causes, nonfatal MI, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina pectoris or heart failure | 0.88 | 0.81–0.96 | 948 vs 1062 | verified |
| Retinopathy complications Retinopathy: need for retinal photocoagulation or treatment with intravitreal agents, vitreous hemorrhage, or onset of diabetes-related blindness | 1.15 | 0.87–1.52 | 106 vs 92 | verified |
| Coronary revascularisation Coronary revascularization | 0.91 | 0.80–1.04 | 405 vs 441 | verified |
| Hospitalisation for unstable angina Hospitalization for unstable angina pectoris | 0.98 | 0.76–1.26 | 122 vs 124 | verified |
Verbatim quotes (11)
- 3-point MACE · Abstract; Results, Cardiovascular Outcomes; Table 1
The primary outcome occurred in significantly fewer patients in the liraglutide group (608 of 4668 patients [13.0%]) than in the placebo group (694 of 4672 [14.9%]) (hazard ratio, 0.87; 95% CI, 0.78 to 0.97
- Cardiovascular death · Results, Cardiovascular Outcomes; Table 1
Death from cardiovascular causes occurred in fewer patients in the liraglutide group (219 patients [4.7%]) than in the placebo group (278 [6.0%]) (hazard ratio, 0.78; 95% CI, 0.66 to 0.93
- All-cause death · Results, Cardiovascular Outcomes; Table 1
The rate of death from any cause was also lower in the liraglutide group (381 patients [8.2%]) than in the placebo group (447 [9.6%]) (hazard ratio, 0.85; 95% CI, 0.74 to 0.97
- Myocardial infarction · Table 1
Myocardial infarction § 292 (6.3) 1.6 339 (7.3) 1.9 0.86 (0.73–1.00) 0.046
- Stroke · Table 1
Stroke § 173 (3.7) 1.0 199 (4.3) 1.1 0.86 (0.71–1.06) 0.16
- Hospitalisation for heart failure · Table 1
Hospitalization for heart failure 218 (4.7) 1.2 248 (5.3) 1.4 0.87 (0.73–1.05) 0.14
- Kidney composite · Table 1; Results, Microvascular Outcomes
Nephropathy 268 (5.7) 1.5 337 (7.2) 1.9 0.78 (0.67–0.92) 0.003
- Expanded MACE (MACE + HF hosp. + revasc. + UA) · Table 1
Expanded composite outcome ‡ 948 (20.3) 5.3 1062 (22.7) 6.0 0.88 (0.81–0.96)
- Retinopathy complications · Table 1, microvascular outcomes
Retinopathy 106 (2.3) 0.6 92 (2.0) 0.5 1.15 (0.87–1.52)
- Coronary revascularisation · Table 1
Coronary revascularization 405 (8.7) 2.3 441 (9.4) 2.5 0.91 (0.80–1.04)
- Hospitalisation for unstable angina · Table 1
Hospitalization for unstable angina pectoris 122 (2.6) 0.7 124 (2.7) 0.7 0.98 (0.76–1.26)
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: LEADER. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/leader/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.